Because our cohort did not include pure CIS cases, further studies are needed to examine whether the expression levels of p‐TFCP2L1 and CDK1 in pure CIS cases are also associated with clinical outcomes, such as recurrence‐free survival and progression to proper muscle‐invasive tumors. This evidence concerns the gene CDK1 and in situ carcinoma.